Nearly three years into the global pandemic of SARS-CoV-2, the epidemiological situation continues to evolve rapidly and dynamically. The COVID-19 crisis has placed the in vitro diagnostics (IVD) industry at the forefront of the fight against the epidemic, fully demonstrating the strong sense of social responsibility, mission-driven commitment, and R&D innovation capabilities of numerous leading IVD enterprises.

The COVID-19 pandemic has also brought unprecedented dividends to the in vitro diagnostics (IVD) industry. Therefore:① How can new development opportunities be explored and high-growth momentum sustained in the era of normalized pandemic control? ② What changes will occur in investment opportunities and trends within the IVD industry? ③ Where do the future “new” business opportunities lie in the field of in vitro diagnostics?

On June 7, byPashanhu Academy, Haoyue Capital, Hangzhou iCampusandVCBeatCo-hosted by“New” Business Opportunities in In Vitro DiagnosticsLive broadcast officially launched.

This live broadcast invited senior corporate leaders, investors, and experts in the field of in vitro diagnostics to jointly discussNew Opportunities for In Vitro Diagnostic Companies in the Era of Normalized Epidemic Prevention and Control. Rejecting superficial discussions, we aim to foster a dynamic exchange of perspectives among on-site guests,Delving Deep into the Challenges Facing Practitioners: Clearing the Fog。

● In the post-pandemic era, how can molecular diagnostics companies achieve sustained innovation?

● How vast is the potential for molecular diagnostics to expand into infectious diseases and other therapeutic areas?

● What insights have the frequent investment and M&A activities in the IVD sector over the past two years provided for the industry and enterprises?

● What is the investment logic in the post-pandemic era?

● What investment opportunities remain in the pathogen detection market?

● How to view Chinese IVD companies expanding into overseas markets?

◆ How should we view the continuous stream of IPO news from molecular diagnostics companies and their upstream raw material suppliers?

◆ What changes have occurred in the logic and style of China’s A-share market before and after the pandemic, and what insights can be drawn?

◆ What is the trend of future healthcare/IVD in the secondary market, and where are the opportunities for enterprises and investors?

This live stream features leaders from in vitro diagnostic companies and industry investors, engaging in on-air debates and discussions.

Guest List:

The WeChat Channels live broadcast series from Pashanhu Society will continue to present themed live sessions, featuring clashing viewpoints, debates on current affairs, and discussions on hot topics. Everyone is welcome to participate!

Focusing on the health and wellness startup sector, we leverage accelerators, private advisory boards, management consensus workshops, and entrepreneurial communities as platforms to integrate core startup elements—including industry resources, capital, and talent within the health and wellness sector. Our mission is to accelerate the growth of entrepreneurs and their organizations, establishing a “New Whampoa” for health and wellness entrepreneurship.

The team has been dedicated to the field of healthcare startup services for six years, having served nearly 700 startup enterprises to date.